Insights into pediatric rhabdomyosarcoma research: Challenges and goals
Year: 2019
Type: article
Abstract: Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.
Source: Pediatric Blood & Cancer
DOI: 10.1002/pbc.27869
Authors: Marielle E. Yohe, Christine M. Heske, Elizabeth Stewart, Peter C. Adamson, Nabil Ahmed, Cristina R. Antonescu, Eleanor Chen, Natalie Collins, Alan Ehrlich, Rene L. Galindo, Berkley E. Gryder, Heidi Hahn, Sharon Hammond, Mark E. Hatley, Douglas S. Hawkins, Madeline N. Hayes, Andrea Hayes‐Jordan, Lee J. Helman, Simone Hettmer, Myron S. Ignatius, Charles Keller, Javed Khan, David G. Kirsch, Corinne M. Linardic, Philip J. Lupo, Rossella Rota, Jack F. Shern, Janet Shipley, Sivasish Sindiri, Stephen J. Tapscott, Christopher R. Vakoc, Leonard H. Wexler, David M. Langenau
Institutions: National Institutes of Health, National Cancer Institute, St. Jude Children's Research Hospital, Children's Hospital of Philadelphia, Baylor College of Medicine, Texas Children's Hospital, Memorial Sloan Kettering Cancer Center, University of Washington, Boston Children's Hospital, The University of Texas Southwestern Medical Center, Universitätsmedizin Göttingen, Seattle Children's Hospital, Fred Hutch Cancer Center, Massachusetts General Hospital, University of North Carolina at Chapel Hill, Children's Hospital of Los Angeles, Children's Cancer Therapy Development Institute, Duke University, Bambino Gesù Children's Hospital, Istituti di Ricovero e Cura a Carattere Scientifico, Institute of Cancer Research, Cold Spring Harbor Laboratory
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2953324065